| General | Administration of PAC-1 at 5 mg with low and steady releasing significantly inhibits the growth of ACHN renal cancer xenograft in mice. Oral administration of PAC-1 (50 or 100 mg/kg) significantly retards tumor growth of NCI-H226 lung cancer xenograft in a dose-dependent manner, and markedly prevents the cancer cells from infiltrating the lung tissue. |
|---|
| Animal model | Mice s.c. injected with NCI-H226 (lung cancer) cells |
|---|
| Formulation | Mixed with cholesterol and pelleted into a 3-mm-diameter 20-mg (total weight) pellet, or dissolved in a mixture of 24:1 vegetable oil/DMSO |
|---|
| Dosages | 0, 50 or 100 mg/kg; |
|---|
| Administration | p.o.; q.d., for 21 days |
|---|
| References | [1] Putt KS, et al. Nat Chem Biol, 2006, 2(10), 543-550. |
|---|
m.cnreagent.com
